Dyadic(DYAI)

Focus: Dyadic is a public biotechnology company focused on biologics and vaccines for infectious diseases, operating at pre-revenue scale with $3M in annual revenue and $7M cash on hand.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Dyadic

AI assessmentNot Hiring

No open roles listed right now. Follow Dyadic to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$3M

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Dyadic

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

58% R&D intensity signals deep commitment to discovery and development in high-impact infectious disease and vaccine space
Public company status provides liquidity, transparency, and potential for equity upside as pipeline advances
Small, focused team in emerging biologics field offers opportunity to build foundational capabilities from ground level

Watch Out For

Pre-revenue business model with $5.8M-$6.8M annual net losses indicates extended runway to profitability and restructuring risk if funding dries up
Zero active clinical trials and no disclosed pipeline programs suggest early-stage operations with limited near-term catalysts for career acceleration
Minimal hiring activity (0 open roles at time of analysis) indicates limited immediate employment opportunities and potential resource constraints

Generated by Claude from Dyadic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

R&D Spend

$2M(58%)38%

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo